TWEET by @CellCentric
Another clinical site open: Simon Pacey and the CCTC team, Cambridge. p300/CBP inhibitor CCS1477 to treat targeted tumours & prostate cancer. pic.twitter.com/2rPQmqNdAV
TWEET by @CellCentric
Evaluating CCS1477 to treat haematological malignancies, another site open. First in class p300/CBP inhibitor to treat multiple myeloma, AML, lymphomas. pic.twitter.com/SUrVRfswUy
TWEET by @CellCentric
Our latest blog on our recent CCS1477 publication in Cancer Discovery. Lab to patients, a massive team effort. cellcentric.com/updates/blog-n… pic.twitter.com/tXvnfX9fg8
TWEET by @CellCentric
Great collaborative effort with @ICR_London and @TJUHospital @SKCCDirector: new strategy to treat prostate cancer through targeting p300/CBP. cancerdiscovery.aacrjournals.org/content/early/… pic.twitter.com/CLWvY2CZk2
TWEET by @CellCentric
Just published: cornerstone publication in Cancer Discovery: targeting p300/CBP with novel drug CCS1477 to treat prostate cancer. cancerdiscovery.aacrjournals.org/content/early/… pic.twitter.com/nSmaio78f0
TWEET by @CellCentric
Great to collaborate with @PCR_News and speak with @benm_d about epigenetics and drug development, lab to patients. Podcast: prostate-cancer-research.org.uk/prostate-pod-w… pic.twitter.com/fwFV9HSM9R
